Clinical Trial Update: Caffeine for Excessive Daytime Somnolence in Parkinson's Disease [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trials studied caffeine for Excessive daytime somnolence in Parkinson's disease. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Somnolence
• Parkinson Disease

Drugs mentioned

• Caffeine (caffeine)

Snippet

Sponsor: Ron Postuma | Conditions: Parkinson's Disease, Excessive Daytime Somnolence | Phase 2, Phase 3 | Status: COMPLETED